The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy
The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy
复制标题
DOI：
10.1038/clpt.2012.57
复制
发表时间：
2012-07-01
影响因子：
6.7
通讯作者：
Niemi, M.
中科院分区：
文献类型：
--
作者：
Wilke, R. A.;Ramsey, L. B.;Niemi, M.
他汀类药物治疗降低胆固醇是现代医学中最伟大的公共卫生成就之一。辛伐他汀是最常用的处方药之一。SLCO1B1中的非同义编码单核苷酸多态性（SNP）rs4149056显著增加辛伐他汀的全身暴露和肌肉毒性风险。本指南探讨了rs4149056（c.521T>C，p.V174A）与所有他汀类药物临床结局之间的关系。辛伐他汀引起肌病的证据强度很高。我们相应地限制了我们的建议。
Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.